Magnetics Business & Technology - September/October 2020 - 10

FEATURE ARTICLE

TDK Ventures Invests in Biomagnetic Medical Imaging Company Genetesis
outcomes research, and obtain evidence to support private
insurance coverage.

Magnetocardiography technology company, Genetesis, is the
latest investment by TDK Corporation's $50 million venture
fund which the company established last year. It is the first
investment by TDK Ventures in the healthcare space and ties in
closely with recent advancements by TDK in the development
of ultra-sensitive biomagnetic imaging sensors.
Two earlier investments were made in electric aviation startup,
AutoFlightX, and e-mobility robotics company, Starship. Both
companies incorporate magnetics technology into their fledgling, disruptive products.
Ohio-based Genetesis develops advanced medical imaging
solutions for cardiac diagnostics. It is positioned to leverage
TDK's global reach and expertise in biomagnetic sensors, piezo
actuators, magnetic noise suppression, MEMS technologies
and electronics, said the company. It fits the venture fund's
mission to invest in innovative startups focusing on digital and
energy transformation and contributing to sustainability.

"TDK's rich history in magnetics and its
recent breakthroughs in biomagnetics at
picoTesla levels makes them one of our
strongest partners to date," said Shrivastava, CEO and founder of Genetesis. "We
are committed to bring the most accurate diagnostics that can assist emerPeeyush Shrivastava,
gency physicians and cardiologists in
CEO and Founder of
making the best decisions for cardiac
Genetesis
health in a non-invasive and a rapid
fashion. We are elated to have TDK as
our strategic partner because of their pioneering work in magnetic materials and its commercialization. Their recent leadership around supporting frontier-tech entrepreneurs caught our
attention and we are excited about this next chapter."
According to Managing Director Nicolas
Sauvage, TDK Ventures investigated
and researched companies with the most
accurate, rapid and non-invasive cardiac
diagnostics with potential for adoption by
hospitals worldwide. Genetesis unlocks
a spectrum of use cases in chest pain
triage and cardiac diagnostics that
Nicolas Sauvage,
provide both immediate and lasting
Managing Director,
patient benefit, and enables a clear,
Genetesis
profitable business case for hospitals
and payers.
"Genetesis' Cardioflux system will save lives and reduce
costs for emergency departments, as well as free up valuable
resources like beds otherwise allocated for overnight observations in hospitals - invaluable in pandemic situations such as
the one we have today with COVID-19," Sauvage noted.
TDK's biomagnetic sensing technology

Its CardioFlux system detects tiny biomagnetic signals of the
heart produced by cardiac tissue's electrical activity when
pumping blood. Within minutes, it identifies if patients with chest
pain need interventional cardiac procedures, and ones that
can be sent home safely. The imaging device is comprised of a
magnetic shield and an array of 36 magnetic sensors to isolate
and measure the heart's magnetic field.

TDK's magnetoresistive magnetic sensor unit (upper left) and a
64ch MR magnetic sensor array

Founded in 2013 by Peeyush Shrivastava and three other
co-founders, the company installed its first prototype system at
Michigan's Ascension Hospital in 2017 to generate initial clinical
results. Notable milestones include FDA approval of its MCG
and HIPAA-compliant Faraday Cloud system which analyzes
and displays the results, CMS reimbursement from Medicare,
and two in-progress clinical trials. Genetesis aims to install
more than 10 systems in 2020 to continue clinical studies for
newer diagnostics, gather real-world data on health economic

Sensors are one of TDK's key technologies and the company is
focused on development of a wide variety of sensors for various
applications. One of these is a high sensitivity magnetic sensor capable of measuring very weak biomagnetic fields. This
technology can open up the possibility of finding solutions to
problems such as the existence of heart disease in an unborn
infant, which cannot be discovered using an existing electrocardiograph, or ischemic heart disease which is difficult to detect at
an early stage.

Magnetics Business & Technology * September/October 2020 www.MagneticsMag.com

http://www.MagneticsMag.com

Magnetics Business & Technology - September/October 2020

Table of Contents for the Digital Edition of Magnetics Business & Technology - September/October 2020